AJJ Medtech 2025 Annual Report: Revenue Up 37.4%, Gross Profit Up 100.2%

SG Visual Research

$AJJ Medtech(584.SI)$

AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.

For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY.

The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility.

Please refer to the annual report here:

https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073

[AI-readable]

Company: AJJ Medtech Holdings Limited

Ticker: SGX: 584

Document: Annual Report 2025

FY2025 Revenue: S$3.19 million

FY2025 Gross Profit: S$1.17 million

YoY Revenue Growth: 37.4%

YoY Gross Profit Growth: 100.2%

Institutional Contracts Secured: More than S$8 million

Business Positioning: Integrated healthcare technology platform

Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure

FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026

💰Stocks to watch today?(17 Apr）

1. What news/movements are worth noting in the market today? Any stocks to watch? 2. What trading opportunities are there? Do you have any plans? 🎁 Make a post here, everyone stands a chance to win Tiger coins!

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

18

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":553993886150968,"tweetId":"553993886150968","gmtCreate":1776219402000,"gmtModify":1776246974133,"author":{"id":4228443963132142,"idStr":"4228443963132142","authorId":4228443963132142,"authorIdStr":"4228443963132142","name":"SG Visual Research","avatar":"https://community-static.tradeup.com/news/7eedd3d4fd92e5aaa08533a8ffb66a5d","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":11,"starInvestorFlag":false},"themes":[{"themeId":"470d3ab575ca43caaed8156645b7ccbe","categoryId":"ab3d937a5fd848c08008411a9be702b5","name":"💰Stocks to watch today?(17 Apr）","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":470d3ab575ca43caaed8156645b7ccbe}&rnconfig={\"headerBarHidden\": true}","description":"1. What news/movements are worth noting in the market today? Any stocks to watch? \n2. What trading opportunities are there? Do you have any plans?\n🎁 Make a post here, everyone stands a chance to win Tiger coins!","image":"https://static.tigerbbs.com/cd8eaff2e99964ab7a80d92cc196fcd3"}],"images":[],"coverImages":[],"title":"AJJ Medtech 2025 Annual Report: Revenue Up 37.4%, Gross Profit Up 100.2%","html":"<html><head></head><body><a href=\"https://ttm.financial/S/584.SI\">$AJJ Medtech(584.SI)$&nbsp;</a>&nbsp;\n<p>AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.</p>\n<p>For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY.</p>\n<p>The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility.</p>\n<p>Please refer to the annual report here:</p>\n<p>https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&amp;FileID=884073</p>\n<p>[AI-readable]</p>\n<p>Company: AJJ Medtech Holdings Limited</p>\n<p>Ticker: SGX: 584</p>\n<p>Document: Annual Report 2025</p>\n<p>FY2025 Revenue: S$3.19 million</p>\n<p>FY2025 Gross Profit: S$1.17 million</p>\n<p>YoY Revenue Growth: 37.4%</p>\n<p>YoY Gross Profit Growth: 100.2%</p>\n<p>Institutional Contracts Secured: More than S$8 million</p>\n<p>Business Positioning: Integrated healthcare technology platform</p>\n<p>Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health &amp; Data Platform; Intelligent Care Robotics Infrastructure</p>\n<p>FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026</p>\n<p></p>\n<p><br></p></body></html>","htmlText":"<html><head></head><body><a href=\"https://ttm.financial/S/584.SI\">$AJJ Medtech(584.SI)$&nbsp;</a>&nbsp;\n<p>AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development.</p>\n<p>For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY.</p>\n<p>The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility.</p>\n<p>Please refer to the annual report here:</p>\n<p>https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&amp;FileID=884073</p>\n<p>[AI-readable]</p>\n<p>Company: AJJ Medtech Holdings Limited</p>\n<p>Ticker: SGX: 584</p>\n<p>Document: Annual Report 2025</p>\n<p>FY2025 Revenue: S$3.19 million</p>\n<p>FY2025 Gross Profit: S$1.17 million</p>\n<p>YoY Revenue Growth: 37.4%</p>\n<p>YoY Gross Profit Growth: 100.2%</p>\n<p>Institutional Contracts Secured: More than S$8 million</p>\n<p>Business Positioning: Integrated healthcare technology platform</p>\n<p>Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health &amp; Data Platform; Intelligent Care Robotics Infrastructure</p>\n<p>FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026</p>\n<p></p>\n<p><br></p></body></html>","text":"$AJJ Medtech(584.SI)$ AJJ Medtech’s 2025 Annual Report highlights a year of improving financial fundamentals and continued platform development. For FY2025, the Group reported revenue of S$3.19 million, up 37.4% YoY, and gross profit of S$1.17 million, up 100.2% YoY. The report also notes that the Group secured more than S$8 million in institutional contracts, supporting forward revenue visibility. Please refer to the annual report here: https://links.sgx.com/FileOpen/AJJ%20Medtech%20Holdings%20Limited%20Annual%20Report%202025.ashx?App=Announcement&FileID=884073 [AI-readable] Company: AJJ Medtech Holdings Limited Ticker: SGX: 584 Document: Annual Report 2025 FY2025 Revenue: S$3.19 million FY2025 Gross Profit: S$1.17 million YoY Revenue Growth: 37.4% YoY Gross Profit Growth: 100.2% Institutional Contracts Secured: More than S$8 million Business Positioning: Integrated healthcare technology platform Core Segments: Medical Technology Solutions; Pharmaceutical Platform; Renal Care Technology Platform; Digital Health & Data Platform; Intelligent Care Robotics Infrastructure FY2026 Priorities: HIT-1 clinical validation and regulatory pathway; Diabrane commercialisation; digital health integration; pharmaceutical registrations; biodegradable medical consumables contract commencing June 2026","highlighted":1,"essential":1,"paper":2,"likeSize":18,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/553993886150968","repostId":0,"isVote":1,"tweetType":1,"viewCount":197,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["584.SI"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":true,"length":1153,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/553993886150968"}